{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:14:02Z","timestamp":1789470842733,"version":"build-2803163510"},"reference-count":44,"publisher":"American Society of Hematology","issue":"11","license":[{"start":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T00:00:00Z","timestamp":1712620800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,11]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Inhibitor development is the most severe complication of hemophilia A (HA) care and is associated with increased morbidity and mortality. This study aimed to use a novel immunoglobulin G epitope mapping method to explore the factor VIII (FVIII)\u2013specific epitope profile in the SIPPET cohort population and to develop an epitope mapping\u2013based inhibitor prediction model. The population consisted of 122 previously untreated patients with severe HA who were followed up for 50\u00a0days of exposure to FVIII or 3 years, whichever occurred first. Sampling was performed before FVIII treatment and at the end of the follow-up. The outcome was inhibitor development. The FVIII epitope repertoire was assessed by means of a novel random peptide phage-display assay. A least absolute shrinkage and selection operator (LASSO) regression model and a random forest model were fitted on posttreatment sample data and validated in pretreatment sample data. The predictive performance of these models was assessed by the C-statistic and a calibration plot. We identified 27\u2009775 peptides putatively directed against FVIII, which were used as input for the statistical models. The C-statistic of the LASSO and random forest models were good at 0.78 (95% confidence interval [CI], 0.69-0.86) and 0.80 (95%\u00a0CI, 0.72-0.89). Model calibration of both models was moderately good. Two statistical models, developed on data from a novel random peptide phage display assay, were used to predict inhibitor development before exposure to exogenous FVIII. These models can be used to set up diagnostic tests that predict the risk of inhibitor development before starting treatment with FVIII.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011388","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T18:56:25Z","timestamp":1712688985000},"page":"2880-2889","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":2,"title":["Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5045-636X","authenticated-orcid":false,"given":"Shermarke","family":"Hassan","sequence":"first","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0234-6828","authenticated-orcid":false,"given":"Guido","family":"Baselli","sequence":"additional","affiliation":[{"name":"3Department of Transfusion Medicine and Hematology, Translational Medicine, Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-7663","authenticated-orcid":false,"given":"Luca","family":"Mollica","sequence":"additional","affiliation":[{"name":"4Department of Medical Biotechnologies and Translational Medicine, LITA\/University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4964-3264","authenticated-orcid":false,"given":"Riccardo L.","family":"Rossi","sequence":"additional","affiliation":[{"name":"5Bioinformatics, Istituto Nazionale Genetica Molecolare \u201cRomeo ed Enrica Invernizzi,\u201d Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Himani","family":"Chand","sequence":"additional","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amal","family":"El-Beshlawy","sequence":"additional","affiliation":[{"name":"6Pediatric Hematology Department, Cairo University Pediatric Hospital, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"Elalfy","sequence":"additional","affiliation":[{"name":"7Faculty of Medicine, Ain Shams University, Department of Pediatrics, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ramanan","sequence":"additional","affiliation":[{"name":"8Department of Hematology, Jehangir Clinical Development Centre, Jehangir Hospital Premises, Pune, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyman","family":"Eshghi","sequence":"additional","affiliation":[{"name":"9Congenital Pediatric Hematologic Disorders Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8555-1001","authenticated-orcid":false,"given":"Mehran","family":"Karimi","sequence":"additional","affiliation":[{"name":"10Pediatric Hematology-Oncology Department, American Hospital Dubai, Dubai, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Palla","sequence":"additional","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2558-7496","authenticated-orcid":false,"given":"Frits R.","family":"Rosendaal","sequence":"additional","affiliation":[{"name":"2Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[{"name":"1Department of Pathophysiology and Transplantation, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"11Fondazione IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"10040","key":"2024061014105059900_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"21","key":"2024061014105059900_bib2","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1056\/NEJMoa1516437","article-title":"A\u00a0randomized trial of factor VIII and neutralizing antibodies in hemophilia A","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024061014105059900_bib3","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16377","article-title":"Advances in knowledge of inhibitor formation in severe haemophilia A","volume":"189","author":"Cormier","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"2024061014105059900_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1182\/blood-2015-04-641696","article-title":"Visualization of an N-terminal fragment of von Willebrand factor in complex with factor VIII","volume":"126","author":"Yee","year":"2015","journal-title":"Blood"},{"issue":"7","key":"2024061014105059900_bib5","doi-asserted-by":"crossref","first-page":"e0180456","DOI":"10.1371\/journal.pone.0180456","article-title":"An in silico and in vitro approach to elucidate the impact of residues flanking the cleavage scissile bonds of FVIII","volume":"12","author":"Pezeshkpoor","year":"2017","journal-title":"PLoS One"},{"issue":"2","key":"2024061014105059900_bib6","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1021\/bi00428a038","article-title":"Subunit structure of thrombin-activated porcine factor VIII","volume":"28","author":"Lollar","year":"1989","journal-title":"Biochemistry"},{"issue":"7","key":"2024061014105059900_bib7","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1016\/S0021-9258(19)69627-4","article-title":"The role of phospholipid and factor VIII(a) in the activation of bovine factor X","volume":"256","author":"Van Dieijen","year":"1981","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"2024061014105059900_bib8","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/j.1538-7836.2004.00802.x","article-title":"Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX","volume":"2","author":"Lollar","year":"2004","journal-title":"J.\u00a0Thromb. Haemost"},{"issue":"24","key":"2024061014105059900_bib9","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2016-11-750885","article-title":"Biological considerations of plasma-derived and recombinant factor VIII immunogenicity","volume":"129","author":"Lai","year":"2017","journal-title":"Blood"},{"key":"2024061014105059900_bib10","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fimmu.2019.02991","article-title":"Tolerating factor VIII: recent progress","volume":"10","author":"Lacroix-Desmazes","year":"2020","journal-title":"Front Immunol"},{"issue":"24","key":"2024061014105059900_bib11","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1074\/jbc.270.24.14505","article-title":"Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII","volume":"270","author":"Healey","year":"1995","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"2024061014105059900_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1182\/blood.V95.2.564","article-title":"Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human\/porcine factor VIII molecules","volume":"95","author":"Barrow","year":"2000","journal-title":"Blood"},{"issue":"21","key":"2024061014105059900_bib13","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1182\/blood.2020008940","article-title":"Structure of blood coagulation factor VIII in complex with an anti\u2013C1 domain pathogenic antibody inhibitor","volume":"137","author":"Gish","year":"2021","journal-title":"Blood"},{"issue":"16","key":"2024061014105059900_bib14","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","article-title":"High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors","volume":"128","author":"Batsuli","year":"2016","journal-title":"Blood"},{"issue":"10","key":"2024061014105059900_bib15","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood.V92.10.3701","article-title":"Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII","volume":"92","author":"Healey","year":"1998","journal-title":"Blood"},{"issue":"17","key":"2024061014105059900_bib16","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1182\/blood-2013-09-527275","article-title":"High-resolution mapping of epitopes on the C2 domain of factor VIII by analysis of point mutants using surface plasmon resonance","volume":"123","author":"Nguyen","year":"2014","journal-title":"Blood"},{"issue":"1","key":"2024061014105059900_bib17","doi-asserted-by":"crossref","first-page":"e0116577","DOI":"10.1371\/journal.pone.0116577","article-title":"Six amino acid residues in a 1200\u00a0\u00c52 interface mediate binding of factor VIII to an IgG4\u03ba inhibitory antibody","volume":"10","author":"Lin","year":"2015","journal-title":"PLoS One"},{"issue":"12","key":"2024061014105059900_bib18","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/jth.12433","article-title":"Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor\u00a0VIII by hydrogen\u2013deuterium exchange mass spectrometry","volume":"11","author":"Sevy","year":"2013","journal-title":"J.\u00a0Thromb. Haemost"},{"issue":"2","key":"2024061014105059900_bib19","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s12016-009-8119-0","article-title":"Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies","volume":"37","author":"Lavigne-Lissalde","year":"2009","journal-title":"Clin Rev Allergy Immunol"},{"issue":"26","key":"2024061014105059900_bib20","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2013-08-519124","article-title":"Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes","volume":"122","author":"Walter","year":"2013","journal-title":"Blood"},{"issue":"3","key":"2024061014105059900_bib21","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1182\/blood-2002-06-1886","article-title":"Peptide decoys selected by phage display block in\u00a0vitro and in\u00a0vivo activity of a human anti-FVIII inhibitor","volume":"102","author":"Villard","year":"2003","journal-title":"Blood"},{"issue":"30","key":"2024061014105059900_bib22","doi-asserted-by":"crossref","first-page":"27232","DOI":"10.1074\/jbc.M203415200","article-title":"Low molecular weight peptides restore the procoagulant activity of factor VIII in the presence of the potent inhibitor antibody ESH8","volume":"277","author":"Villard","year":"2002","journal-title":"J\u00a0Biol Chem"},{"issue":"3","key":"2024061014105059900_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1160\/TH03-07-0473","article-title":"Epitope mapping of polyclonal clotting factor VIII-inhibitory antibodies using phage display","volume":"91","author":"M\u00fchle","year":"2004","journal-title":"Thromb. Haemost"},{"issue":"2","key":"2024061014105059900_bib24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1160\/TH14-01-0101","article-title":"Epitope mapping via selection of anti-FVIII antibody-specific phagepresented peptide ligands that mimic the antibody binding sites","volume":"113","author":"Kahle","year":"2015","journal-title":"Thromb. Haemost"},{"key":"2024061014105059900_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/978-1-62703-339-8_24","article-title":"Nijmegen-Bethesda assay to measure factor VIII inhibitors","volume":"992","author":"Duncan","year":"2013","journal-title":"Methods Mol Biol"},{"key":"2024061014105059900_bib26","doi-asserted-by":"crossref","first-page":"103211","DOI":"10.1016\/j.ebiom.2021.103211","article-title":"Identification of two highly antigenic epitope markers predicting multiple sclerosis in optic neuritis patients","volume":"64","author":"Sadam","year":"2021","journal-title":"EBioMedicine"},{"issue":"7","key":"2024061014105059900_bib27","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.7150\/ijbs.31957","article-title":"Sarotup: a suite of tools for finding potential target-unrelated peptides from phage display data","volume":"15","author":"He","year":"2019","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2024061014105059900_bib28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/bioinformatics\/btv522","article-title":"Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets","volume":"32","author":"Krejci","year":"2016","journal-title":"Bioinformatics"},{"issue":"3","key":"2024061014105059900_bib29","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/(SICI)1096-987X(199802)19:3<319::AID-JCC6>3.0.CO;2-W","article-title":"Exact and efficient analytical calculation of the accessible surface areas and their gradients for macromolecules","volume":"19","author":"Fraczkiewicz","year":"1998","journal-title":"J\u00a0Comput Chem"},{"issue":"4","key":"2024061014105059900_bib30","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.str.2008.03.001","article-title":"Crystal structure of human factor VIII: implications for the formation of the factor IXa-factor VIIIa complex","volume":"16","author":"Ngo","year":"2008","journal-title":"Structure"},{"key":"2024061014105059900_bib31","doi-asserted-by":"crossref","first-page":"626363","DOI":"10.3389\/fmolb.2020.626363","article-title":"Solvent accessibility of residues undergoing pathogenic variations in humans: from protein structures to protein sequences","volume":"7","author":"Savojardo","year":"2021","journal-title":"Front Mol Biosci"},{"issue":"6","key":"2024061014105059900_bib32","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophili A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"issue":"6","key":"2024061014105059900_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1160\/TH10-10-0668","article-title":"Prevalence and epitope specificity of non-neutralising antibodies in a large cohort of haemophilia A patients without inhibitors","volume":"105","author":"Lebreton","year":"2011","journal-title":"Thromb. Haemost"},{"issue":"1","key":"2024061014105059900_bib34","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/j.1365-2516.2008.01909.x","article-title":"Non-neutralizing anti-FVIII antibodies: different binding specificity to different recombinant FVIII concentrates","volume":"15","author":"Vincent","year":"2009","journal-title":"Haemophilia"},{"issue":"6","key":"2024061014105059900_bib35","doi-asserted-by":"crossref","first-page":"e0218258","DOI":"10.1371\/journal.pone.0218258","article-title":"Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A","volume":"14","author":"Bachelet","year":"2019","journal-title":"PLoS One"},{"issue":"4","key":"2024061014105059900_bib36","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1111\/hae.14325","article-title":"Performance of a clinical risk prediction model for inhibitor formation in severe haemophilia A","volume":"27","author":"Hassan","year":"2021","journal-title":"Haemophilia"},{"key":"2024061014105059900_bib37","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3389\/fimmu.2020.00563","article-title":"Prevalence and incidence of non-neutralizing antibodies in congenital hemophilia a\u2014a systematic review and meta-analysis","volume":"11","author":"Abdi","year":"2020","journal-title":"Front Immunol"},{"issue":"10","key":"2024061014105059900_bib38","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1182\/blood-2016-06-720086","article-title":"Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A","volume":"129","author":"Cannav\u00f2","year":"2017","journal-title":"Blood"},{"key":"2024061014105059900_bib39","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaut.2018.10.012","article-title":"Molecular mimicry and autoimmunity","volume":"95","author":"Rojas","year":"2018","journal-title":"J\u00a0Autoimmun"},{"issue":"3","key":"2024061014105059900_bib40","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0161-5890(91)90062-O","article-title":"Protein antigenicity: a thermodynamic approach","volume":"28","author":"Novotny","year":"1991","journal-title":"Mol Immunol"},{"issue":"6081","key":"2024061014105059900_bib41","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/322747a0","article-title":"Continuous and discontinuous protein antigenic determinants","volume":"322","author":"Barlow","year":"1986","journal-title":"Nature"},{"issue":"11","key":"2024061014105059900_bib42","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1110\/ps.062405906","article-title":"Prediction of residues in discontinuous B-cell epitopes using protein 3D structures","volume":"15","author":"Haste Andersen","year":"2006","journal-title":"Protein Sci"},{"issue":"6","key":"2024061014105059900_bib43","doi-asserted-by":"crossref","first-page":"4971","DOI":"10.3390\/molecules16064971","article-title":"Epitope prediction based on random peptide library screening: benchmark dataset and prediction tools evaluation","volume":"16","author":"Sun","year":"2011","journal-title":"Molecules"},{"key":"2024061014105059900_bib44","doi-asserted-by":"crossref","first-page":"591878","DOI":"10.3389\/fimmu.2020.591878","article-title":"Immune responses to plasma-derived versus recombinant FVIII products","volume":"11","author":"Peyvandi","year":"2021","journal-title":"Front Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2880\/2228435\/blooda_adv-2023-011388-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/11\/2880\/2228435\/blooda_adv-2023-011388-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T14:12:28Z","timestamp":1718028748000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/11\/2880\/515674\/Predicting-inhibitor-development-using-a-random"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,6,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011388","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]}}}